AHNAK2 and cancer: It has previously been observed that AHNAK2 is overexpressed in many cancers and acts as a poor prognostic biomarker in clear cell renal cell carcinoma (ccRCC), pancreatic ductal carcinoma (PDAC), papillary thyroid carcinoma (PTC), and lung adenocarcinoma (LUAD) (12–14).